flutamide has been researched along with buserelin in 53 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 17 (32.08) | 18.7374 |
| 1990's | 33 (62.26) | 18.2507 |
| 2000's | 2 (3.77) | 29.6817 |
| 2010's | 1 (1.89) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Fleshner, NE; Trachtenberg, J | 1 |
| Schmeller, N | 1 |
| Armitage, TG; Cooper, EH; Denis, L; Newling, DW; Richards, BR; Robinson, MR; Smith, PH; Sylvester, R | 1 |
| Bono, A; Carneiro de Moura, JL; De Pauw, M; Denis, L; Keuppens, F; Mahler, C; Newling, D; Robinson, M; Smith, P; Sylvester, R | 1 |
| Baldelli, S; Cellerino, R; Menichetti, ET; Miseria, S; Murer, B; Torresi, U; Tummarello, D | 1 |
| Fischer, M; Flamm, J; Höltl, W; Pflüger, H; Tomschi, W | 1 |
| Altwein, JE; Boccardo, F; Haefliger, JM; Holdaway, IM; Jordaan, JP; Klippel, F; Lunglmayr, G; Tyrrell, CJ; Varenhorst, E | 1 |
| Horlbeck, R; Jurincic, CD; Klippel, KF | 1 |
| Andrade, JA; Oliveira, MG; Oliveira, PD; Pina, F; Pina-Cabral, JM | 1 |
| Berná, L; Blanco, R; Carrió, I; Estorch, M; Germá, JR; Torres, G | 1 |
| Denis, L | 2 |
| Ayub, M; Levell, MJ | 1 |
| Armitage, TG; Bono, A; Calais da Silva, F; Debruyne, F; Denis, L; Robinson, P; Smith, PH; Sylvester, R | 1 |
| De Pauw, M; Denis, L; Newling, DW; Robinson, MR; Sylvester, R | 1 |
| Christensen, I; Denis, L; Iversen, P; Suciu, S; Sylvester, R | 2 |
| Bond, A; Carvalho, AP; De Pauw, M; Denis, L; Keuppens, F; Newling, D; Ongena, P; Smith, P; Sylvester, R; Vermeylen, K | 1 |
| Christensen, MG; Friis, E; Hornbøl, P; Hvidt, V; Iversen, HG; Iversen, P; Klarskov, P; Krarup, T; Lund, F; Mogensen, P | 1 |
| Schulze, H; Senge, T | 1 |
| Bono, A; De Pauw, M; Denis, L; Keuppens, F; Mahler, C; Newling, D; Pinto de Carvalho, AP; Robinson, M; Smith, P; Sylvester, R | 1 |
| D'Eramo, G; Di Silverio, F; Sciarra, F | 1 |
| Hwang, YS; John, MJ; Krall, JM; McGowan, D; Perez, CA; Pilepich, MV | 1 |
| Bono, A; De Moura, JL; De Pauw, M; Denis, L; Keuppens, F; Mahler, C; Newling, D; Robinson, M; Smith, P; Sylvester, R | 1 |
| Guidez, C | 1 |
| Lunglmayr, G | 2 |
| Bono, A; De Moura, JL; De Pauw, M; Denis, L; Keuppens, F; Mahler, C; Newling, DW; Robinson, M; Smith, PH; Sylvester, R | 1 |
| Iversen, P | 1 |
| Cariou, G; Coloby, P; Colombel, P; Coulange, C; Fourcade, RO; Grise, P; Mangin, P; Poterre, M; Soret, JY | 1 |
| Boccardo, F; Cortellini, P; Decensi, A; Delli Ponti, U; Giuliani, L; Guarneri, D; Martorana, G; Oneto, F; Petracco, S; Rubagotti, A | 1 |
| Elder, JS; Gibbons, RP | 1 |
| Bono, A; Carvalho, AP; de Moura, JL; De Pauw, M; Denis, L; Newling, D; Ongena, P; Smith, P; Sylvester, R | 1 |
| Waxman, J | 1 |
| Ceda, GP; Ceresini, G; Cortellini, P; Denti, L; Hoffman, AR; Valenti, G | 1 |
| Abel, P; Cox, J; Farah, N; Fleming, J; Hewitt, G; O'Donoghue, EP; Sandow, J; Sikora, K; Waxman, J; Williams, G | 1 |
| Aaronson, N; Da Silva, FC | 1 |
| Kaldenhoff, H; Schulze, H; Senge, T | 1 |
| Bouffioux, C | 1 |
| Alioth, H; Müller, J; Senn, E | 1 |
| Belanger, A; Borsanyi, JP; Dupont, A; Emond, J; Giguere, M; Labrie, F; Lacourciere, Y; Monfette, G | 1 |
| Bandhauer, K; Hadziselimović, F; Senn, E | 1 |
| Lynch, JH; O'Brien, WM | 1 |
| Doberauer, C; Niederle, N; Schmidt, CG | 1 |
| Belanger, A; Dupont, A; Giguere, M; Labrie, F; Lachance, R | 1 |
| Soloway, MS | 1 |
| Castagnetti, G; Dotti, A; Ferrari, G; Ferrari, P; Pollastri, CA; Tavoni, F | 1 |
| Gold, E; Goulding, A | 1 |
| Brun, E; Caputo, M; Castello, R; Furlani, L; Magnani, CM; Moghetti, P; Muggeo, M; Negri, C; Tosi, F | 1 |
| de Voogt, H; Denis, L; Sylvester, RJ | 1 |
| Belanger, A; Chertin, B; Farkas, A; Fridmans, A; Hartman, H; Labrie, F; Spitz, IM | 1 |
| Brower, V | 1 |
| Duensing, S; Grüllich, C; Hadaschik, BA; Höfner, T; Hohenfellner, M; Jäger, D; Pahernik, S; Vallet, S | 1 |
1 review(s) available for flutamide and buserelin
| Article | Year |
|---|---|
[LHRH agonists combined with antiandrogens in the treatment of metastasizing prostatic carcinoma].
Topics: Androgen Antagonists; Animals; Buserelin; Cyproterone; Cyproterone Acetate; Dogs; Drug Therapy, Combination; Flutamide; Humans; Male; Neoplasm Metastasis; Orchiectomy; Prostatic Neoplasms; Rats; Receptors, Cell Surface; Receptors, LHRH | 1985 |
29 trial(s) available for flutamide and buserelin
| Article | Year |
|---|---|
Total androgen ablation: European experience. The EORTC GU Group.
Topics: Aged; Buserelin; Flutamide; Goserelin; Humans; Male; Middle Aged; Neoplasm Metastasis; Orchiectomy; Prostatic Neoplasms | 1991 |
Complete androgen deprivation prior to radical prostatectomy in patients with stage T3 cancer of the prostate.
Topics: Aged; Buserelin; Combined Modality Therapy; Flutamide; Gonadotropin-Releasing Hormone; Goserelin; Humans; Male; Pilot Projects; Preoperative Care; Prostatectomy; Prostatic Neoplasms; Time Factors | 1991 |
A multicenter randomized trial comparing the luteinizing hormone-releasing hormone analogue goserelin acetate alone and with flutamide in the treatment of advanced prostate cancer. The International Prostate Cancer Study Group.
Topics: Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Buserelin; Delayed-Action Preparations; Drug Tolerance; Flutamide; Goserelin; Humans; Male; Prostatic Neoplasms; Remission Induction; Time Factors; United Kingdom | 1991 |
Combined treatment (goserelin plus flutamide) versus monotherapy (goserelin alone) in advanced prostate cancer: a randomized study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Buserelin; Carcinoma; Flutamide; Follow-Up Studies; Goserelin; Humans; Male; Middle Aged; Prostatic Neoplasms; Remission Induction; Survival Rate | 1991 |
Some limitations of the radioisotope bone scan in patients with metastatic prostatic cancer. A subanalysis of EORTC trial 30853. The EORTC Urological Group.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Buserelin; Flutamide; Follow-Up Studies; Goserelin; Humans; Male; Orchiectomy; Prostatic Neoplasms; Radionuclide Imaging; Randomized Controlled Trials as Topic; Survival Rate | 1990 |
Comparability of EORTC and DAPROCA studies in advanced prostatic cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Buserelin; Flutamide; Goserelin; Humans; Male; Orchiectomy; Prostatic Neoplasms; Randomized Controlled Trials as Topic; Survival Rate | 1990 |
Zoladex and flutamide versus bilateral orchiectomy. A randomized phase III EORTC 30853 study. The EORTC GU Group.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Buserelin; Flutamide; Goserelin; Humans; Male; Middle Aged; Multicenter Studies as Topic; Orchiectomy; Prognosis; Prostatic Neoplasms; Radionuclide Imaging; Randomized Controlled Trials as Topic; Survival Rate | 1990 |
A phase III trial of zoladex and flutamide versus orchiectomy in the treatment of patients with advanced carcinoma of the prostate.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Buserelin; Flutamide; Follow-Up Studies; Goserelin; Humans; Male; Middle Aged; Orchiectomy; Prostatic Neoplasms; Randomized Controlled Trials as Topic; Survival Rate | 1990 |
Zoladex and flutamide versus orchiectomy in the treatment of advanced prostatic cancer. A combined analysis of two European studies, EORTC 30853 and DAPROCA 86.
Topics: Antineoplastic Combined Chemotherapy Protocols; Buserelin; Flutamide; Goserelin; Humans; Male; Orchiectomy; Prostatic Neoplasms; Randomized Controlled Trials as Topic; Survival Rate | 1990 |
Complete androgen blockade: data from an EORTC 30853 trial.
Topics: Aged; Anilides; Buserelin; Combined Modality Therapy; Europe; Flutamide; Goserelin; Humans; Male; Middle Aged; Multicenter Studies as Topic; Orchiectomy; Prostatic Neoplasms; Randomized Controlled Trials as Topic; Survival Rate | 1990 |
Advanced prostatic cancer: clinical and hormonal response to flutamide in patients pretreated with LHRH analogue and cyproterone acetate.
Topics: Aged; Androgen Antagonists; Anilides; Buserelin; Clinical Trials as Topic; Cyproterone; Cyproterone Acetate; Drug Therapy, Combination; Flutamide; Goserelin; Humans; Male; Middle Aged; Prostatic Neoplasms; Random Allocation | 1990 |
Phase II Radiation Therapy Oncology Group study of hormonal cytoreduction with flutamide and Zoladex in locally advanced carcinoma of the prostate treated with definitive radiotherapy.
Topics: Buserelin; Diarrhea; Flutamide; Goserelin; Humans; Male; Prostatic Neoplasms; Radiotherapy | 1990 |
Orchidectomy versus Zoladex plus Eulexin in patients with metastatic prostate cancer (EORTC 30853).
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Buserelin; Drug Combinations; Drug Evaluation; Europe; Flutamide; Goserelin; Humans; Male; Orchiectomy; Prostatic Neoplasms; Risk Factors | 1990 |
[How can a nursing team participate in a clinical trial? Zoladex, flutamide trial].
Topics: Buserelin; Clinical Trials as Topic; Flutamide; Goserelin; Humans; Job Description; Male; Nursing Staff, Hospital; Prostatic Neoplasms | 1990 |
A multicenter trial comparing the luteinizing hormone releasing hormone analog Zoladex, with Zoladex plus flutamide in the treatment of advanced prostate cancer. The International Prostate Cancer Study Group.
Topics: Buserelin; Flutamide; Goserelin; Humans; Male; Prostatic Neoplasms | 1990 |
Orchidectomy vs. Zoladex plus flutamide in patients with metastatic prostate cancer. The EORTC GU Group.
Topics: Aged; Alanine Transaminase; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Buserelin; Carcinoma; Combined Modality Therapy; Flutamide; Follow-Up Studies; Goserelin; Humans; Liver Function Tests; Male; Orchiectomy; Prospective Studies; Prostatic Neoplasms; Survival Rate | 1990 |
Zoladex plus flutamide vs. orchidectomy for advanced prostatic cancer. Danish Prostatic Cancer Group (DAPROCA).
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Buserelin; Combined Modality Therapy; Flutamide; Follow-Up Studies; Goserelin; Humans; Male; Middle Aged; Orchiectomy; Prostatic Neoplasms; Survival Rate | 1990 |
Total androgen blockade with Zoladex plus flutamide vs. Zoladex alone in advanced prostatic carcinoma: interim report of a multicenter, double-blind, placebo-controlled study.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Buserelin; Double-Blind Method; Flutamide; Follow-Up Studies; Goserelin; Humans; Male; Middle Aged; Prostatic Neoplasms; Survival Rate | 1990 |
Zoladex with or without flutamide in the treatment of locally advanced or metastatic prostate cancer: interim analysis of an ongoing PONCAP study. Italian Prostatic Cancer Project (PONCAP).
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Buserelin; Flutamide; Follow-Up Studies; Goserelin; Humans; Male; Neoplasm Staging; Prostatic Neoplasms; Survival Rate | 1990 |
Zoladex and flutamide vs orchidectomy: a phase III EORTC 30853 trial. EORTC Urological Group.
Topics: Anilides; Buserelin; Clinical Trials as Topic; Europe; Flutamide; Goserelin; Humans; Male; Multicenter Studies as Topic; Orchiectomy; Prognosis; Prospective Studies; Prostatic Neoplasms; Random Allocation | 1989 |
'Zoladex' versus 'Zoladex' plus flutamide in the treatment of advanced prostate cancer. First interim analysis of an international trial. International Prostate Cancer Study Group.
Topics: Aged; Anilides; Buserelin; Clinical Trials as Topic; Drug Therapy, Combination; Flutamide; Goserelin; Humans; International Cooperation; Male; Multicenter Studies as Topic; Prognosis; Prostatic Neoplasms; Random Allocation | 1989 |
Short-term anti-androgen therapy and very long-acting depot gonadotrophin-releasing hormone agonist for prostatic cancer.
Topics: Aged; Aged, 80 and over; Androgen Antagonists; Buserelin; Clinical Trials as Topic; Cyproterone; Cyproterone Acetate; Delayed-Action Preparations; Flutamide; Humans; Male; Middle Aged; Prostatic Neoplasms; Random Allocation | 1989 |
The clinical and endocrine assessment of three different antiandrogen regimens combined with a very long-acting gonadotrophin-releasing hormone analogue.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Buserelin; Cyproterone; Cyproterone Acetate; Delayed-Action Preparations; Flutamide; Humans; Male; Middle Aged; Neoplasm Metastasis; Neoplasms, Hormone-Dependent; Phosphoric Monoester Hydrolases; Prostatic Neoplasms; Random Allocation; Testosterone | 1988 |
Quality of life assessment in prostatic cancer.
Topics: Buserelin; Clinical Trials as Topic; Europe; Flutamide; Goserelin; Humans; Male; Orchiectomy; Prostatic Neoplasms; Quality of Life; Surveys and Questionnaires | 1988 |
Evaluation of total versus partial androgen blockade in the treatment of advanced prostatic cancer.
Topics: Androgen Antagonists; Androgens; Buserelin; Flutamide; Goserelin; Humans; Male; Multicenter Studies as Topic; Orchiectomy; Prospective Studies; Prostatic Neoplasms; Random Allocation | 1988 |
Total androgen blockade in advanced prostatic cancer. Critical review and personal experience.
Topics: Androgen Antagonists; Buserelin; Cyproterone; Cyproterone Acetate; Flutamide; Goserelin; Humans; Male; Multicenter Studies as Topic; Orchiectomy; Prostatic Neoplasms; Time Factors | 1988 |
Advantages of the combination therapy in previously untreated and treated patients with advanced prostate cancer.
Topics: Androgen Antagonists; Antineoplastic Agents; Buserelin; Clinical Trials as Topic; Combined Modality Therapy; Diethylstilbestrol; Flutamide; Follow-Up Studies; Gonadotropin-Releasing Hormone; Humans; Leuprolide; Male; Neoplasm Staging; Orchiectomy; Prostatic Neoplasms; Triptorelin Pamoate | 1986 |
Combination treatment in M1 prostate cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Buserelin; Flutamide; Humans; Male; Middle Aged; Prostatic Neoplasms; Testosterone | 1993 |
The importance of prognostic factors in the interpretation of two EORTC metastatic prostate cancer trials. European Organization for Research and Treatment of Cancer (EORTC) Genito-Urinary Tract Cancer Cooperative Group.
Topics: Aged; Analysis of Variance; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Buserelin; Combined Modality Therapy; Cyproterone Acetate; Disease-Free Survival; Flutamide; Goserelin; Humans; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Multivariate Analysis; Neoplasm Staging; Orchiectomy; Prognosis; Proportional Hazards Models; Prostatic Neoplasms; Risk Assessment; Survival Rate | 1998 |
23 other study(ies) available for flutamide and buserelin
| Article | Year |
|---|---|
Sequential androgen blockade: a biological study in the inhibition of prostatic growth.
Topics: 5-alpha Reductase Inhibitors; Androstenes; Animals; Azasteroids; Buserelin; Clusterin; Finasteride; Flutamide; Glycoproteins; Male; Molecular Chaperones; Organ Size; Prostate; Random Allocation; Rats; Rats, Sprague-Dawley; Seminal Vesicles | 1992 |
[A 79-year-old man with metastatic prostate cancer, treated with Zoladex, flutamide, calcitonin and Ostac, suffers from frequent troublesome sweating with palpitation and angina pectoris, especially at night. Is there a therapy?].
Topics: Aged; Androgen Antagonists; Angina Pectoris; Buserelin; Calcitonin; Cyproterone; Cyproterone Acetate; Flutamide; Goserelin; Humans; Hyperhidrosis; Male; Prostatic Neoplasms | 1992 |
Prostatic specific antigen and the prediction of prognosis in metastatic prostatic cancer.
Topics: Antigens, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Bone Neoplasms; Buserelin; Flutamide; Goserelin; Humans; Male; Orchiectomy; Predictive Value of Tests; Prognosis; Prostate-Specific Antigen; Prostatic Neoplasms; Radionuclide Imaging; Survival Rate | 1990 |
Lymphangitic carcinomas of the lung as presentation of prostatic cancer. A case report.
Topics: Buserelin; Carcinoma; Flutamide; Goserelin; Humans; Lung Neoplasms; Lymphangitis; Male; Middle Aged; Prostatic Neoplasms | 1991 |
Proteins C and S in patients with advanced prostatic cancer.
Topics: Buserelin; Carrier Proteins; Complement C4b; Complement Inactivator Proteins; Flutamide; Glycoproteins; Humans; Male; Orchiectomy; Prostatic Neoplasms; Protein C; Protein S | 1991 |
Bone marrow regeneration after hormonal therapy in patients with bone metastases from prostate carcinoma.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal; Bone Marrow; Bone Neoplasms; Buserelin; Flutamide; Goserelin; Humans; Male; Middle Aged; Organotechnetium Compounds; Prostatic Neoplasms; Radionuclide Imaging; Regeneration | 1991 |
Maximal androgen blockade in prostatic cancer.
Topics: Androgen Antagonists; Buserelin; Flutamide; Goserelin; Humans; Imidazoles; Imidazolidines; Leuprolide; Male; Orchiectomy; Prostatic Neoplasms | 1991 |
Suppression of plasma androgens by the antiandrogen flutamide in prostatic cancer patients treated with Zoladex, a GnRH analogue.
Topics: 17-alpha-Hydroxyprogesterone; Aged; Aged, 80 and over; Androgens; Androstenedione; Anilides; Antineoplastic Agents; Buserelin; Dehydroepiandrosterone; Depression, Chemical; Flutamide; Goserelin; Humans; Hydroxyprogesterones; Male; Orchiectomy; Prostatic Neoplasms; Testosterone | 1990 |
EORTC protocol 30853: orchidectomy versus zoladex plus flutamide in the management of metastatic carcinoma of the prostate. Interim statistical analysis of the side effects of treatment.
Topics: Antineoplastic Combined Chemotherapy Protocols; Buserelin; Flutamide; Goserelin; Humans; Male; Neoplasm Metastasis; Orchiectomy; Prostatic Neoplasms | 1990 |
Influence of different types of antiandrogens on luteinizing hormone-releasing hormone analogue-induced testosterone surge in patients with metastatic carcinoma of the prostate.
Topics: Acid Phosphatase; Aged; Androgen Antagonists; Buserelin; Cyproterone; Cyproterone Acetate; Drug Therapy, Combination; Flutamide; Goserelin; Humans; Luteinizing Hormone; Male; Premedication; Prostatic Neoplasms; Testosterone; Time Factors | 1990 |
Advances in the treatment of metastatic prostatic cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Buserelin; Diethylstilbestrol; Flutamide; Gonadotropin-Releasing Hormone; Humans; Imidazoles; Male; Neoplasm Metastasis; Orchiectomy; Palliative Care; Prostatic Neoplasms | 1985 |
Androgens do not regulate the growth hormone response to GHRH in elderly men.
Topics: Aged; Aging; Antineoplastic Combined Chemotherapy Protocols; Buserelin; Flutamide; Goserelin; Growth Hormone; Growth Hormone-Releasing Hormone; Humans; Male; Middle Aged; Prostatic Neoplasms; Testosterone | 1989 |
LHRH analogues in combination with an anti-androgen in the treatment of advanced disease.
Topics: Androgen Antagonists; Buserelin; Drug Therapy, Combination; Flutamide; Goserelin; Humans; Male; Prostatic Neoplasms | 1989 |
Effect of treatment with chronic gonadotropin releasing hormone agonist on human testis.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Buserelin; Flutamide; Humans; Leydig Cells; Male; Sertoli Cells; Spermatogenesis; Spermatogonia; Spermatozoa; Testis | 1987 |
Hydroxyproline as a marker for following patients with metastatic prostate cancer.
Topics: Bone Neoplasms; Buserelin; Creatinine; Flutamide; Follow-Up Studies; Gonadotropin-Releasing Hormone; Humans; Hydroxyproline; Leuprolide; Male; Prostatic Neoplasms | 1988 |
Advanced male breast cancer treatment with the LH-RH analogue buserelin alone or in combination with the antiandrogen flutamide.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Buserelin; Estradiol; Flutamide; Follicle Stimulating Hormone; Humans; Luteinizing Hormone; Male; Middle Aged; Testosterone | 1988 |
Long term treatment with luteinising hormone releasing hormone agonists and maintenance of serum testosterone to castration concentrations.
Topics: Bone Neoplasms; Buserelin; Flutamide; Gonadotropin-Releasing Hormone; Humans; Luteinizing Hormone; Male; Prostatic Neoplasms; Radioimmunoassay; Testosterone; Time Factors; Triptorelin Pamoate | 1985 |
Newer methods of hormonal therapy for prostate cancer.
Topics: Adenocarcinoma; Aminoglutethimide; Androgen Antagonists; Bone Neoplasms; Buserelin; Flutamide; Gonadotropin-Releasing Hormone; Humans; Leuprolide; Male; Megestrol; Megestrol Acetate; Pituitary Hormone-Releasing Hormones; Prostatic Neoplasms | 1984 |
Flutamide-mediated androgen blockade evokes osteopenia in the female rat.
Topics: Androgens; Animals; Body Weight; Bone Density; Bone Diseases, Metabolic; Buserelin; Female; Flutamide; Hydroxyproline; Organ Size; Rats; Rats, Wistar; Uterus | 1993 |
The insulin resistance in women with hyperandrogenism is partially reversed by antiandrogen treatment: evidence that androgens impair insulin action in women.
Topics: Adult; Androgen Antagonists; Androgens; Buserelin; Female; Flutamide; Glucose Clamp Technique; Humans; Hyperandrogenism; Insulin; Insulin Resistance; Ovulation; Spironolactone | 1996 |
Partial androgen suppression consequent to increased secretion of adrenal androgens in a patient with prostate cancer treated with long-acting GnRH agonists.
Topics: Adenocarcinoma; Aged; Androgen Antagonists; Androgens; Anilides; Buserelin; Diarrhea; Flutamide; Gastrectomy; Glaucoma; Gonadotropin-Releasing Hormone; Hernia, Hiatal; Humans; Luteinizing Hormone; Male; Nitriles; Peptic Ulcer; Prostate-Specific Antigen; Prostatic Neoplasms; Testosterone; Tosyl Compounds | 2009 |
Watchful waiting beats androgen deprivation therapy in early prostate cancer.
Topics: Aged; Androgen Antagonists; Animals; Antineoplastic Agents, Hormonal; Buserelin; Drug Prescriptions; Flutamide; Humans; Imidazolidines; Leuprolide; Male; Patient Education as Topic; Patient Satisfaction; Prostatic Neoplasms; Retrospective Studies; Risk Assessment; Risk Factors; Survival Analysis | 2008 |
Docetaxel followed by abiraterone in metastatic castration-resistant prostate cancer: efficacy and predictive parameters in a large single center cohort.
Topics: Aged; Androgen Antagonists; Androstenes; Anilides; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Buserelin; Cohort Studies; Disease-Free Survival; Docetaxel; Flutamide; Humans; Leuprolide; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Nitriles; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies; Taxoids; Tosyl Compounds; Treatment Outcome; Triptorelin Pamoate | 2015 |